Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Progen Industries Ltd. has maintained that its PI-88 cancer compound has a dual mechanism: inhibition of angiogenesis and tumor metastasis. Teasing out the latter mechanism in humans can
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury